Drugs / INBRX-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03815396 | Jul 2019 → Aug 2022 | alpha 1-antitrypsin deficiency | Inhibrx Biosciences, Inc | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-24 | Inhibrx Biosciences, Inc | Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi investorroom.com ↗ |
| 2024-01-23 | Inhibrx Biosciences, Inc | Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B investorroom.com ↗ |
| 2023-04-26 | Inhibrx Biosciences, Inc | Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials investorroom.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INBRX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03815396 ↗ |
| Known as | rhAAT-Fc | “INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).” NCT03815396 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein” NCT03815396 ↗ |
| Route | Intravenous | “The planned dosing schedule is IV every 3 to 4 weeks.” NCT03815396 ↗ |